Optimizing Anemia Management in Dialysis Patients: Individualizing Therapy and Reducing the Need for Red Cell Transfusion– Evaluate the risks and benefits of Erythropoiesistimulating Agents, iron, and red cell transfusion as strategies for anemia treatment in patients on dialysis in order to individualize and optimize therapy to maintain hemoglobin within the desired range.
Appraise long-term effects associated with red cell transfusion, especially transfusion-induced iron overload and immunomodulation, so that adverse clinical outcomes in patients on dialysis, including future kidney transplant recipients, can be averted.
Use appropriate ESA dosing and iron supplementation according to evidence based clinical findings, pertinent clinical
practice, and regulatory guidelines; in order to improve outcomes and reduce the need for and/or risk associated with red cell transfusion in patients undergoing dialysis.